See full labeling. <4 weeks: not established. ≥4 weeks (≥25kg): one 400mg film-coated tab twice daily. If unable to swallow, can use chew tabs: (25–<28kg): 150mg twice daily; (28–<40kg): 200mg twice daily; ≥40kg: 300mg twice daily. Chew tabs max dose: 300mg twice daily.
Chew tabs or oral susp are not interchangeable with the film-coated tabs. Severe hepatic impairment. Monitor liver aminotransferases, immune reconstitution syndrome (esp. during initial therapy), myopathy, and rhabdomyolysis. Discontinue if signs/symptoms of severe skin or hypersensitivity reactions develop. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Antagonized by rifampin, possibly other strong UGT1A1 inducers. May be potentiated by UGT1A1 inhibitors. Concomitant aluminum and/or magnesium-containing antacids: not recommended. Caution with other drugs that can cause myopathy (eg, statins).
Insomnia, headache, dizziness, nausea, asthenia, fatigue, creatinine kinase elevations, myopathy, rhabdomyolysis; severe skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis), hypersensitivity, others (see full labeling).
Note: Register pregnant patients exposed to raltegravir by calling (800) 258-4263.